Navellier & Associates
AUPH icon

Navellier & Associates’s Aurinia Pharmaceuticals AUPH Stock Holding History

Navellier & Associates’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.52M Sell
155,411
-101,731
-40% -$1.62M 0.21% 117
2026
Q2 		$4.36M Buy
257,142
+142,206
+124% +$2.27M 0.35% 64
2026
Q1 		$1.7M Buy
114,936
+3,250
+3% +$47.5K 0.18% 115
2025
Q4 		$1.78M Buy
111,686
+27,906
+33% +$396K 0.2% 109
2025
Q3 		$926K Buy
+83,780
New +$915K 0.09% 191

Other funds holding AUPH

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Jupiter Asset Management
Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
O'Shaughnessy Asset Management
O'Shaughnessy Asset Management Stamford, Connecticut $23.6B AUM 34.05% 1-Year Est. Return
Hillsdale Investment Management
Hillsdale Investment Management Toronto, Ontario, Canada $4.42B AUM 54.57% 1-Year Est. Return

Navellier & Associates's AUPH Position: Q3 2026 in Review

Navellier & Associates reduced its Aurinia Pharmaceuticals (AUPH) stake by 40% in Q3 2026, selling an estimated $1.62M and leaving 155,411 shares worth $2.52M. The position accounts for 0.21% of the portfolio, ranked #117.

Navellier & Associates first reported a position in AUPH in Q3 2025 and has held it in 5 quarters since. The position peaked at $4.36M in Q2 2026. 190 funds tracked by Wall St. Rank hold AUPH as of Q3 2026.

  • Navellier & Associates held 155,411 shares of Aurinia Pharmaceuticals worth $2.52M as of Q3 2026.
  • Navellier & Associates sold 101,731 Aurinia Pharmaceuticals shares in Q3 2026, an estimated $1.62M.
  • Aurinia Pharmaceuticals made up 0.21% of Navellier & Associates's portfolio in Q3 2026, its #117 holding.
  • Navellier & Associates first reported a position in Aurinia Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • Navellier & Associates's Aurinia Pharmaceuticals position peaked at $4.36M in Q2 2026.
  • 190 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2026.

Based on Navellier & Associates's 13F filing for Q3 2026, filed 12 Nov 2026.